DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Thalassemia Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments" report has been added to ResearchAndMarkets.com's offering.

This report covers more than 24 drugs currently in different phases of development.

The report provides thalassemia treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players.

Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Scope

By Company By Phase By Molecule Type By Region By Route of Administration

Key Topics Covered

1. Introduction

1.1. Research Methodology

1.2. Research Scope

2. Disease Overview

3. Executive Summary

4. Market Dynamics

4.1. Drivers

4.2. Restraints

4.3. Opportunities

5. Pipeline Analysis/Outlook

5.1. Analysis by Company

5.2. Analysis by Phase

Drug Name Generic Name Synonyms Company Collaborator Route of administration Target Mechanism of Action Technology Molecule type CAS Number Weight Chemical Formula IUPAC name ATC code

5.3. By Molecule Type

5.4. Analysis by Region

6. Company Profiling

6.1. Novartis AG

6.2. F. Hoffmann-La Roche Ltd.

6.3. GlaxoSmithKline plc.

6.4. Celgene Corporation

6.5. Acceleron Pharma Inc.

6.6. Sanofi

6.7. Sangamo Therapeutics, Inc.

6.8. Bluebird Bio, Inc.

6.9. Cadila Healthcare Ltd.

6.10. La Jolla Pharmaceuticals Company

6.11. Ionis Pharmaceuticals Inc.

6.12 Imara Inc.

6.13 Gamida Cell

6.14 Alnylam Pharmaceuticals

6.15 Vertex - CRISPR Therapeutics AG

6.16 Biogen

6.17 Protagonist Therapeutics Inc.

6.18 Errant Gene Therapeutics

6.19 Agios Inc.

6.20 Silence Therapeutics

6.21 Calimmune Inc.

6.22 Editas Medicine

6.23 Vifor Pharma

6.24 Kiadis Pharma

For more information about this report visit https://www.researchandmarkets.com/research/f9htsd/thalassemia?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605005773/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Clinical Trials,Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 04:39 AM/DISC: 06/05/2018 04:39 AM

http://www.businesswire.com/news/home/20180605005773/en